ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD)
Clinical trials for ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) explained in plain language.
Never miss a new study
Get alerted when new ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD) trials appear
Sign up with your email to follow new studies for ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Virtual coach boosts lung rehab for rare disease patients
Knowledge-focused CompletedThis study looked at whether using augmented reality (AR) can help people with Alpha-1 antitrypsin deficiency (a rare lung condition) stick to a home breathing and walking program. Fifty adults did breathing exercises twice a day and walked at least 5,000 steps daily for six week…
Matched conditions: ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD)
Sponsor: University of Parma • Aim: Knowledge-focused
Last updated May 11, 2026 20:53 UTC
-
First step toward a treatment for rare lung and liver disease
Knowledge-focused CompletedThis early-stage study tested a new drug called WVE-006 in 47 healthy volunteers to see if it is safe and how the body processes it. The goal is to find the right dose for future studies in people with Alpha-1 Antitrypsin Deficiency, a genetic condition that can damage the lungs …
Matched conditions: ALPHA-1 ANTITRYPSIN DEFICIENCY (AATD)
Phase: PHASE1 • Sponsor: Wave Life Sciences Ltd. • Aim: Knowledge-focused
Last updated May 05, 2026 11:54 UTC